Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, Controlled, prospective study

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2018
This article has no abstract
Epistemonikos ID: 98b0535f3207a93ab4eeb8fb5a57af8cc319457c
First added on: Apr 07, 2025